192 related articles for article (PubMed ID: 3485566)
41. Hamster monoclonal antibodies to murine natural killer cells.
Linnemeyer PA; Tsuji JM; Gill S; Pollack SB
Nat Immun; 1994; 13(1):49-60. PubMed ID: 8111193
[TBL] [Abstract][Full Text] [Related]
42. Mouse natural killer subsets defined by their target specificity and their ability to be separately rendered unresponsive in vivo.
Kung SK; Miller RG
J Immunol; 1997 Mar; 158(6):2616-26. PubMed ID: 9058794
[TBL] [Abstract][Full Text] [Related]
43. AK cells were developed from NK cells during in vitro culture of allogeneic or F1 anti-parental stimulation: functional conversion in recognizing H-2 expression of target cells accompanied by phenotypical conversion.
Taniguchi K; Kawano YI; Nomoto K
Immunology; 1988 Aug; 64(4):669-76. PubMed ID: 2971609
[TBL] [Abstract][Full Text] [Related]
44. Phenotypic and functional characterization of peripheral blood and bone marrow natural killer cells prior to autologous transplantation.
Arbour S; Toupin S; Bélanger R; Gyger M; Hallé JP; Perreault C; Roy DC
Bone Marrow Transplant; 1996 Mar; 17(3):315-22. PubMed ID: 8704680
[TBL] [Abstract][Full Text] [Related]
45. Bone marrow differentiation in vitro.
Schrader JW
Crit Rev Immunol; 1983; 4(3):197-277. PubMed ID: 6141895
[TBL] [Abstract][Full Text] [Related]
46. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
47. Genesis of human oncolytic natural killer cells from primitive CD34+CD33- bone marrow progenitors.
Lotzová E; Savary CA; Champlin RE
J Immunol; 1993 Jun; 150(12):5263-9. PubMed ID: 7685792
[TBL] [Abstract][Full Text] [Related]
48. The in vivo effects of steel factor on natural killer lineage cells in murine spleen and bone marrow.
Miller SC; Fleming WH; Zsebo KM; Weissman IL
Nat Immun; 1993; 12(6):293-301. PubMed ID: 7505667
[TBL] [Abstract][Full Text] [Related]
49. Lymphokine-activated and natural killer cell activity in human intestinal mucosa.
Hogan PG; Hapel AJ; Doe WF
J Immunol; 1985 Sep; 135(3):1731-8. PubMed ID: 3926882
[TBL] [Abstract][Full Text] [Related]
50. In vitro generated mast cells express natural cytotoxicity against tumour cells.
Ghiara P; Boraschi D; Villa L; Scapigliati G; Taddei C; Tagliabue A
Immunology; 1985 Jun; 55(2):317-24. PubMed ID: 3924820
[TBL] [Abstract][Full Text] [Related]
51. Differential expression of lymphokine-activated killer cells and natural killer cells in adoptive transfer experiments utilizing fractionated bone marrow.
Merluzzi VJ; Trail PA; Last-Barney K
J Immunol; 1986 Oct; 137(8):2425-7. PubMed ID: 3531332
[TBL] [Abstract][Full Text] [Related]
52. Lymphokine-induced cytotoxicity: characterization of effectors, precursors, and regulatory ancillary cells.
Ting CC; Yang SS; Hargrove ME
Cancer Res; 1986 Feb; 46(2):513-8. PubMed ID: 3079663
[TBL] [Abstract][Full Text] [Related]
53. Effect of various cytokines and growth factors on the interleukin-2-dependent in vitro differentiation of natural killer cells from bone marrow.
Migliorati G; Cannarile L; Herberman RB; Riccardi C
Nat Immun Cell Growth Regul; 1989; 8(1):48-55. PubMed ID: 2654622
[TBL] [Abstract][Full Text] [Related]
54. Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts.
Klingemann HG; Deal H; Reid D; Eaves CJ
Exp Hematol; 1993 Aug; 21(9):1263-70. PubMed ID: 8330650
[TBL] [Abstract][Full Text] [Related]
55. Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens.
Lanier LL; Benike CJ; Phillips JH; Engleman EG
J Immunol; 1985 Feb; 134(2):794-801. PubMed ID: 3871216
[TBL] [Abstract][Full Text] [Related]
56. Natural killer cell development and function precede alpha beta T cell differentiation in mouse fetal thymic ontogeny.
Carlyle JR; Michie AM; Cho SK; Zúñiga-Pflücker JC
J Immunol; 1998 Jan; 160(2):744-53. PubMed ID: 9580246
[TBL] [Abstract][Full Text] [Related]
57. IL-12 is essential for resistance against Yersinia enterocolitica by triggering IFN-gamma production in NK cells and CD4+ T cells.
Bohn E; Autenrieth IB
J Immunol; 1996 Feb; 156(4):1458-68. PubMed ID: 8568248
[TBL] [Abstract][Full Text] [Related]
58. Expansion of functional NK cells in multiple tissue compartments of mice treated with Flt3-ligand: implications for anti-cancer and anti-viral therapy.
Shaw SG; Maung AA; Steptoe RJ; Thomson AW; Vujanovic NL
J Immunol; 1998 Sep; 161(6):2817-24. PubMed ID: 9743341
[TBL] [Abstract][Full Text] [Related]
59. Changes in tumor-associated NK 1.1+ large granular lymphocyte precursors after cyclophosphamide injection: in vitro characterization and potential therapeutic application.
Krupke DM; Fuller J; Aslakson C; Evans R
Nat Immun; 1994; 13(5):246-57. PubMed ID: 7833624
[TBL] [Abstract][Full Text] [Related]
60. Activation of mouse liver natural killer cells and NK1.1(+) T cells by bacterial superantigen-primed Kupffer cells.
Dobashi H; Seki S; Habu Y; Ohkawa T; Takeshita S; Hiraide H; Sekine I
Hepatology; 1999 Aug; 30(2):430-6. PubMed ID: 10421651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
